Overview

Biohaven Ltd., a biopharmaceutical company headquartered in New Haven, CT, has released its Annual Report on Form 10-K for the fiscal year ended December 31, 2025. The company is focused on the discovery, development, and commercialization of life-changing therapies, and is listed on the New York Stock Exchange under the ticker BHVN.

Key Points for Investors

• Market Capitalization and Public Float: As of the last business day of its most recent second fiscal quarter (June 30, 2025), Biohaven had an aggregate market value of common shares held by non-affiliates of approximately \$1.044 billion, with a share price of \$14.11. As of February 26, 2026, there were 150,417,084 common shares outstanding, indicating significant liquidity and market participation.
• Exchange Listing: Biohaven’s common shares are registered and actively traded on the New York Stock Exchange, further emphasizing its standing as a major player in the biopharma sector.
• Regulatory Compliance: The company confirms it is a well-known seasoned issuer and has filed all required reports in the last 12 months. Biohaven is not a shell company and is not an emerging growth or smaller reporting company, which means it is subject to the most stringent SEC reporting and governance requirements.
• Internal Controls: The annual report includes an attestation by a registered public accounting firm regarding the effectiveness of Biohaven’s internal controls over financial reporting, in compliance with Section 404(b) of the Sarbanes-Oxley Act.

Forward-Looking Statements and Key Risks

The report contains numerous forward-looking statements. Key areas addressed include:

• Ongoing and planned clinical trials, including discovery and proof-of-concept studies, with updates on status and timing of results.
• Research and development plans for new product candidates, with milestone, contingent payment, and royalty payment projections that could affect liquidity.
• Commercialization, marketing, and manufacturing strategies, as well as estimates on future revenues, expenses, and the need for additional financing.
• Market acceptance, competitive positioning, and the potential market size for Biohaven’s product candidates.
• Risks related to economic conditions, including inflation, interest rate volatility, and supply chain costs impacting manufacturing and clinical trial operations.
• Potential impacts from disruptions at regulatory agencies like the FDA, which could delay product approvals or commercialization efforts.
• Tax considerations, including expected timing and amounts of future tax payments and audit conclusions.
• Other factors, such as outcomes from ongoing litigation, intellectual property challenges, and broader industry trends.

Investor Alert: As these are forward-looking statements, actual results may differ materially due to a range of known and unknown risks.

Shareholder Matters and Corporate Structure

• Corporate Details: The company operates under the name Biohaven Ltd. (formerly Biohaven Research Ltd.), incorporated in the state of D8, with its principal executive offices at 215 Church Street, New Haven, CT.
• Share Classes: Only one class of securities, “Common Shares, without par value,” is registered and actively traded.
• Proxy Statement: Portions of the company’s definitive Proxy Statement for the 2024 Annual Meeting of Shareholders are incorporated by reference into the Annual Report, indicating ongoing adherence to governance and disclosure best practices.

Potential Price-Sensitive Information

• Active Pipeline: The company highlights ongoing and upcoming clinical trials and R&D initiatives, which are often catalysts for share price movement in the biotech sector. The timing of trial results, potential regulatory submissions, and commercialization progress can be critical events for investors.
• Financial Flexibility: References to anticipated milestone, contingent, and royalty payments, as well as plans for additional financing, suggest active capital management and potential for strategic transactions.
• Regulatory and Market Risks: The forward-looking risk disclosures regarding regulatory delays, economic headwinds, and competitive dynamics may impact investor sentiment and share value.

Summary Table of Contents

Investors can access sections on Business Overview, Risk Factors, Management’s Discussion and Analysis, Financial Statements, and more for comprehensive details on company operations, financial position, and outlook.

Conclusion: Investor Takeaway

The 2025 Annual Report for Biohaven Ltd. underscores the company’s position as a well-capitalized, actively traded biopharma innovator with a robust pipeline and established governance. Investors should closely monitor upcoming clinical trial results, R&D milestones, and any guidance on commercialization or regulatory updates, as these could significantly impact future share performance.